Stanford University
The objective of this study is to determine whether vinpocetine is safe when taken at higher doses.
The planned study seeks to provide preliminary data to assess the benefits and safety for vinpocetine to address cognitive problems in two groups of patients. One group are patients with epilepsy in whom cognitive problems are common, but there is currently no specific treatment available. Vinpocetine has been shown to improve memory in animals and also has anticonvulsant activity. The other group are people who suffer cognitive/behavioral problems from fetal exposure to alcohol or anticonvulsant drugs. In animals, vinpocetine has been shown to mitigate these deficits. We propose to extend our…
Inclusion Criteria: 1. Healthy adults 18-40 years old. 2. Proficient English. 3. Use of appropriate contraception if woman of childbearing potential. Exclusion Criteria: 1. Major medical disease (e.g., epilepsy, diabetes, heart disease, active cancer, depression). 2. Those who score \>18 overall on the BDI-II or \>0 for item #9 (suicidal thoughts) at screening. 3. Use of centrally active medications. 4. History of allergy to vinpocetine. 5. IQ\<80. 6. BMI≥30. 7. Pregnancy or lactation.
Increasing doses of vinpocetine to assess tolerability.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.